Please use this identifier to cite or link to this item:
Type
ArticleCopyright
Open access
Collections
- BA - IGM - Artigos de Periódicos [3332]
- INI - Artigos de Periódicos [3041]
Metadata
Show full item record
THE EFFECT OF DIABETES AND PREDIABETES ON ANTITUBERCULOSIS TREATMENT OUTCOMES: A MULTICENTER PROSPECTIVE COHORT STUDY
Author
Affilliation
Abstract
Background. It is unclear whether diabetes or prediabetes affects unfavorable treatment outcomes and death in people with
tuberculosis (PWTB).
Methods. Culture-confirmed, drug-susceptible PWTB, enrolled in the Regional Prospective Observational Research in
Tuberculosis (RePORT)–Brazil cohort between 2015 and 2019 (N = 643) were stratified based on glycemic status according to baseline
glycated hemoglobin. Unfavorable tuberculosis (TB) outcome was defined as treatment failure or modification, recurrence, or
death; favorable outcome was cure or treatment completion. We corroborated the findings using data from PWTB reported to the
Brazilian National System of Diseases Notification (SINAN) during 2015–2019 (N = 20 989). Logistic regression models evaluated
associations between glycemic status and outcomes.
Results. In both cohorts, in univariate analysis, unfavorable outcomes were more frequently associated with smoking, illicit
drug use, and human immunodeficiency virus infection. Diabetes, but not prediabetes, was associated with unfavorable outcomes
in the RePORT-Brazil (adjusted relative risk [aRR], 2.45; P < .001) and SINAN (aRR, 1.76; P < .001) cohorts. Furthermore, diabetes
was associated with high risk of death (during TB treatment) in both RePORT-Brazil (aRR, 2.16; P = .040) and SINAN (aRR, 1.93;
P = .001).
Conclusions. Diabetes was associated with an increased risk of unfavorable outcomes and mortality in Brazilian PWTB.
Interventions to improve TB treatment outcomes in persons with diabetes are needed.
Share